Lanean...
Recent advancements in PARP inhibitors-based targeted cancer therapy
Poly(ADP-ribose) polymerase inhibitors (PARPi) are a new class of agents with unparalleled clinical achievement for driving synthetic lethality in BRCA-deficient cancers. Recent FDA approval of PARPi has motivated clinical trials centered around the optimization of PARPi-associated therapies in a va...
Gorde:
| Argitaratua izan da: | Precis Clin Med |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Oxford University Press
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7501589/ https://ncbi.nlm.nih.gov/pubmed/32983586 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/pcmedi/pbaa030 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|